Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CPL500036 in Acute Exacerbation of Schizophrenia
NCT05278156Phase 2Completed
- Sponsor
- Celon Pharma S.A.
- Start
- May 2021
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of cpl500036 in schizophrenia (3 arms), sponsored by Celon Pharma S.A. Primary endpoint: Change from baseline in PANSS positive subscale at 28 days. Started May 2021; status: completed.
02
Drugs
cpl500036
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT05278156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05278156.